SYDNEY, Australia--(BUSINESS WIRE)--Jan. 12, 2006--Proteome Systems (ASX:PXL) today announced an early outcome from its clinical collaboration with the HighQ Foundation in New York is the identification of multiple biomarkers for Huntington’s Disease (HD) using the Proteome Systems discovery platforms. A 2-year human study will now validate these markers which could then be used to accelerate the development of effective new drug treatments for Huntington’s Disease and other neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases.
